Navigation Links
Study defines effective microbicide design for HIV/AIDS prevention

icidal agent.

The model is easily adapted to studying different active ingredients and delivery vehicles simply by changing the data entered, the researchers said. For example, researchers might specify the thickness of the expected coating layer, the initial concentration of microbicide in that layer, and the microbicide's documented ability to bind to and disable the viral particles.

The researchers demonstrated their new tool by applying it to the promising microbicide Cyanovirin-N, a protein with anti-HIV activity that has been well documented by other scientists.

"Our results suggest HIV neutralization is achievable if coating thicknesses on the order of 100 microns remain in place after sex," Geonnotti said. One hundred microns is the approximate width of a human hair. "Increased microbicide concentration and potency hasten viral neutralization and diminish penetration of infectious virus through the coating layer, as do ingredients that restrict viral passage," he said.

"Our findings demonstrate the need to pair potent active ingredients with well-engineered delivery vehicles, and they highlight the importance of the dosage form -- especially its ability to restrict viral diffusion and remain in place -- in microbicide effectiveness," Katz added.

More than 20 microbicidal chemical compounds are now in development or testing and five of them have reached the final phase of clinical trials. The Duke group's new model provides a "rational guide" for design specifications that could further improve such microbicides' ability to cut the rate of HIV spread, the researchers said.

The researchers now are conducting studies to experimentally measure the diffusion of viral particles through various delivery vehicles. They also are collaborating with other researchers on developing high-performance polymer gels that might provide a more substantial physical barrier to HIV.
'"/>

Source:Duke University


Page: 1 2 3

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
3. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
4. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
5. Study Links Ebola Outbreaks To Animal Carcasses
6. Breakthrough Microarray-based Technology for the Study of Cancer
7. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
8. Study finds more than one-third of human genome regulated by RNA
9. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
10. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
11. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works

Post Your Comments:
(Date:12/3/2009)...a personality change in warmer water, according to...hange may make some species more aggressive. , E... Australia,s Great Barrier Reef have shown for the...ently timid, or consistently bold, and that these ...er temperatures rise. , A slight lift of just on...
(Date:12/3/2009)...it comes to investment in energy efficient technol...ces Research Council (EPSRC) Chief Executive Dave ...d engineering research has already brought us fuel...t more investment is needed to develop the capabil... carbon emission targets by 2020 and limit the imp...
(Date:12/2/2009)...turated Latino men have a more difficult time quit...to U.S. culture, but acculturation has no affect o...se findings are published in Cancer Epidemiology,...an Association for Cancer Research. The December i...ation affects smoking cessation differently for La...
Breaking Biology News(10 mins):Fish with attitude: Some like it hot 2Research is vital to a cleaner, greener, low carbon future 2Acculturation affects smoking cessation success among Latinos 2Resuscitation and Survival Rates from Out of Hospital Cardiac Arrest Nearly Double with Comprehensive Treatment Protocol 61476 1Resuscitation and Survival Rates from Out of Hospital Cardiac Arrest Nearly Double with Comprehensive Treatment Protocol 61476 2Resuscitation and Survival Rates from Out of Hospital Cardiac Arrest Nearly Double with Comprehensive Treatment Protocol 61476 3Resuscitation and Survival Rates from Out of Hospital Cardiac Arrest Nearly Double with Comprehensive Treatment Protocol 61476 4Resuscitation and Survival Rates from Out of Hospital Cardiac Arrest Nearly Double with Comprehensive Treatment Protocol 61476 5Resuscitation and Survival Rates from Out of Hospital Cardiac Arrest Nearly Double with Comprehensive Treatment Protocol 61476 6Survey Finds AARP Members Back Health Care Reform Legislation 61472 1Survey Finds AARP Members Back Health Care Reform Legislation 61472 2Gen Probe Announces Webcast of Annual Briefing for Institutional Investors and Financial Analysts 14858 1Gen Probe Announces Webcast of Annual Briefing for Institutional Investors and Financial Analysts 14858 2
...he molecular machines that drive all life, also sh...he study, in the journal Structure , reveals that...y experienced a "big bang" of innovation. The acti...ned with each other or split apart to produce a ho...This explosion of new forms coincided with the rap...
...s animals of the Americas avoid competing for the ...ssible answer comes from a new study by a pair of .... Their large-scale analysis shows that it,s not j...s themselves that have been a driving force in the...ctors as whether species are active daytime or nig...
..., 2009)Attempts to treat critical limb ischemia in...elow-the-knee angioplasty are still thwarted by re...te of angioplasty or stenting), the need for repea...rosclerotic disease, leading to tissue death (gang...have been studying a potential solutionthe use of ...
Other Biology News:Study of protein structures reveals key events in evolutionary history 2American carnivores evolved to avoid each other, new study suggests 2Promising 3-year data: Saving limbs with drug-eluting stents 2Promising 3-year data: Saving limbs with drug-eluting stents 3
(Date:12/2/2009)...Gabon, December 2 , - "Bo...m and Heritage" , Coinciding with the Int...,Gabonese Republic is hosting an international con...guarding biological resources in Africa. The,confe...ders, ministers,scientific experts, private compa...
(Date:12/2/2009)...Mass., Dec. 2 TechConnect World, a...y development and product integration in cleantech...er 11th deadline for technology abstracts and busi...chConnect World, in association with the Nano Scie... Technology and Sustainable Industries Organizatio...
(Date:12/2/2009)...Dec. 2 S*BIO Pte Ltd today announc...itor, SB1518, at The American Society of Hematolog...s. ,, Data will be presented on the clinical re...1518 detailing its safety, tolerability and pharma...levels ranging from 100 to 600 mg. These doses wer...
(Date:12/2/2009)...hina, Dec. 2 /PRNewswire-Asia/ -- Simcere Pharmace... SCR ), a leading pharmaceutical company,specializ...ng of branded,generic and proprietary pharmaceutic...s have been included in China,s National Drug Reim...,s Ministry of Human Resources and Social,Security...
Breaking Biology Technology:Libreville International Conference 2-3 June 2010 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3
..., Human plasma and serum represents an impo...iagnosis. However, the wide dynamic range in prote...nge in the development of diagnostic assays for ,...roteins in the presence of high , abundan... to remove 99% , of the diagnostically un...
...acy Worzella and Brad Larson , Promega Co... , Application Note 139 ... , Multiplexing homogeneous cell-based a...ers from a single sample well , Monitoring... Assay miniaturization up to 1536-well format...
...rjan Orban 1 , Francois Degorce 2 and Jean-Luc ,...many; 2 Cisbio international, France , ... , Rev. 12/2005 , ...pathway investigation under HTS conditions , ...r with the HTRF , IP-One assay in terms...
Other Biology Technology:Protein Depletion for Plasma and Serum Proteomic Analysis 2Protein Depletion for Plasma and Serum Proteomic Analysis 3Protein Depletion for Plasma and Serum Proteomic Analysis 4Protein Depletion for Plasma and Serum Proteomic Analysis 5Protein Depletion for Plasma and Serum Proteomic Analysis 6Protein Depletion for Plasma and Serum Proteomic Analysis 7Protein Depletion for Plasma and Serum Proteomic Analysis 8Protein Depletion for Plasma and Serum Proteomic Analysis 9Protein Depletion for Plasma and Serum Proteomic Analysis 10Protein Depletion for Plasma and Serum Proteomic Analysis 11Protein Depletion for Plasma and Serum Proteomic Analysis 12Protein Depletion for Plasma and Serum Proteomic Analysis 13Protein Depletion for Plasma and Serum Proteomic Analysis 14Protein Depletion for Plasma and Serum Proteomic Analysis 15Protein Depletion for Plasma and Serum Proteomic Analysis 16Protein Depletion for Plasma and Serum Proteomic Analysis 17Protein Depletion for Plasma and Serum Proteomic Analysis 18Protein Depletion for Plasma and Serum Proteomic Analysis 19Protein Depletion for Plasma and Serum Proteomic Analysis 20Protein Depletion for Plasma and Serum Proteomic Analysis 21Protein Depletion for Plasma and Serum Proteomic Analysis 22Protein Depletion for Plasma and Serum Proteomic Analysis 23Protein Depletion for Plasma and Serum Proteomic Analysis 24Protein Depletion for Plasma and Serum Proteomic Analysis 25Protein Depletion for Plasma and Serum Proteomic Analysis 26Protein Depletion for Plasma and Serum Proteomic Analysis 27Protein Depletion for Plasma and Serum Proteomic Analysis 28Protein Depletion for Plasma and Serum Proteomic Analysis 29Protein Depletion for Plasma and Serum Proteomic Analysis 30Protein Depletion for Plasma and Serum Proteomic Analysis 31Protein Depletion for Plasma and Serum Proteomic Analysis 32Promegas Multiplexed Luciferase Reporter and Cell Viability Assays performed on the PHERAstar 2Promegas Multiplexed Luciferase Reporter and Cell Viability Assays performed on the PHERAstar 3Promegas Multiplexed Luciferase Reporter and Cell Viability Assays performed on the PHERAstar 4Promegas Multiplexed Luciferase Reporter and Cell Viability Assays performed on the PHERAstar 5
...ains 200 g of lyophilized peptide derived from the...ds 380-402; GLTPSAWEASSLRSSRHSGLSHF. This peptid...s EP1 receptor polyclonal antibody (Catalog No. 10...ibody to block protein-antibody complex formation ...
Goat Anti-Mouse Ig + IgM Antibody, FITC Conjugated from Cayman Chemical
Rabbit Anti-TRBP1 Polyclonal Antibody, Unconjugated from ProSci, Inc
Donor feline Serum - 100mL from GeneTex
Biology Products: